JHVEPhoto/iStock Editorial via Getty Images
Novo Nordisk (NVO) has received approval to market its oral GLP-1 medicine Rybelsus in the U.S. to reduce the risk of major cardiovascular events such as stroke in adults with type 2 diabetes, the Danish drugmaker announced.
Having first approved
